DEA telemedicine rules, state medical practice acts, licensing requirements by location, and DEA registration costs for controlled substances.
The Dangerous Assumption About Telehealth Peptide Prescribing A clinic in Florida prescribes peptides via telehealth to a patient in California. The clinic owner thinks: "The DEA extended telemedicine flexibilities through 2026, so we're fine." Six months later, the California Medical Board sends a cease-and-desist letter. The clinic is practicing medicine without a license in California. This scenario plays out monthly. Clinics confuse DEA rules with state medical licensing rules, and that confusion costs them money and patient access. Here's the critical distinction that most peptide clinic owners get wrong: **Most peptides are not controlled substances**. The DEA doesn't regulate them. Your state medical board does. And state medical boards require you to be licensed where your patient is located, not where your clinic is located.
Let's start with what the DEA actually regulates. The DEA only controls substances listed in the Controlled Substances Act (CSA). Most peptides are not on that list. BPC-157, TB-500, AOD-9604, Selank, Cerebrolysin, and dozens of others fall outside DEA jurisdiction entirely.
The DEA's telemedicine extension through December 31, 2026 applies to controlled substances only—primarily Schedule II-V substances like certain opioids or stimulants. If you're prescribing peptides that aren't controlled, the DEA extension is irrelevant to you.
But here's where clinics go astray: they assume "the DEA said telehealth is OK" means "telehealth peptide prescribing is OK everywhere." It doesn't.
Peptides fall under state medical practice acts. Each state defines what constitutes "practicing medicine" and requires physicians to be licensed in the state where the patient is located. This is the actual regulatory framework governing your prescribing.
Here's the operational requirement: If you prescribe peptides to a patient in California, you must be licensed to practice medicine in California. Period. If you're a Florida-licensed physician running a telehealth clinic, you cannot prescribe to California patients without a California medical license (or without using a California-licensed physician as a supervising practitioner).
Some states have telemedicine-friendly medical practice acts. Others do not. Some states allow out-of-state practitioners to provide telemedicine without licensure if certain conditions are met (typically a prior in-person relationship). California does not fall into that category.
The practical result: if you want to prescribe peptides via telehealth nationally, you need to be licensed in every state where you have patients, or you need to partner with licensed practitioners in those states.
If you're prescribing a controlled substance peptide (a rare scenario, but it exists), the DEA registration requirement applies. A DEA registration costs $731 for three years and is state-specific. If you're registered in Florida but prescribing controlled substance peptides to patients in five states, you need DEA registration in all five states.
Most peptide clinics don't deal with controlled substance peptides, so this is not your primary constraint. But if you're working with any compound that might be controlled, verify its DEA status. Don't assume.
If you want to scale peptide prescribing via telehealth across multiple states, here's the operational framework:
Option 1: Multi-State Licensure
Become licensed in every state where you have (or want to have) patients. This is expensive and cumbersome, but it's the most direct path. Medical licensing fees vary by state, but plan for $500–$2,000 per state license, plus renewal costs.
Option 2: Partnerships with State-Licensed Practitioners
Partner with physicians licensed in each target state. They serve as supervising practitioners or co-prescribers. Your telemedicine platform connects patients with local practitioners. This is more scalable but requires recruiting or partnering with licensed practitioners in multiple states.
Option 3: Narrow Geographic Scope
Focus on states where you're licensed. Accept geographic limitations. This is the most conservative approach and reduces compliance risk dramatically.
Option 4: In-Person Requirement
Require an in-person initial visit in your jurisdiction. Some state medical boards allow out-of-state telehealth prescribing if there's a prior in-person relationship. Verify this for your specific state.
Mistake 1: Assuming Telemedicine = No Licensing Required
This is the error that gets clinics shut down. Telemedicine is still medicine. It's still regulated by state medical boards.
Mistake 2: Thinking a Prior Relationship Negates Licensure Requirements
Some states allow this; most don't. Don't assume. Consult your state medical board or an attorney licensed in the states where you operate.
Mistake 3: Ignoring Multi-Practitioner Compliance
If your clinic has multiple providers and they're prescribing across state lines, each provider needs to meet licensure requirements. One provider's multi-state licensure doesn't cover another provider's multi-state prescribing.
Mistake 4: Forgetting Nurse Practitioners and Physician Assistants
If you're using NPs or PAs, they're also subject to state scope-of-practice rules and licensure requirements. Supervision requirements vary by state. A supervised NP in one state might not be legally permitted to prescribe peptides in another state.
Some peptide derivatives or pharmaceutical peptides are scheduled controlled substances. For example, certain pharmaceutical peptides used in other contexts may fall under Schedule IV. If you're prescribing any controlled substance, DEA registration is mandatory.
Verify the DEA status of every peptide you prescribe. The DEA's Orange Book and the DEA's website maintain the Controlled Substances List. If a peptide doesn't appear there, it's not controlled. But if it does, you're under DEA jurisdiction in addition to state medical board jurisdiction.
Even if you're compliant with licensure requirements, state medical boards increasingly track telehealth prescribing. Some states require you to register with the medical board before offering telemedicine. Others require you to report out-of-state telemedicine activity.
Maintain documentation of your licensure status in each state and your compliance with that state's telehealth requirements. This becomes critical if you're ever audited or if a patient complaint is filed.
Before you add a single patient in a new state, verify:
1. Your licensure status in that state
2. That state's telemedicine medical practice rules
3. Whether the peptide(s) you prescribe are controlled substances
4. Any DEA registration requirements
5. Any state-specific reporting requirements
This takes time. But it's far cheaper than a cease-and-desist letter from a state medical board.
---
*This article is for informational and educational purposes only. It does not constitute medical, legal, or financial advice. Clinic operators should consult qualified legal counsel, compliance advisors, and medical boards for guidance specific to their practice and jurisdiction. MyProtocolStack is a protocol tracking and blood work analysis platform — it is not a medical device and does not provide clinical recommendations.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers -- not generic charts.
Start Free →